¼¼°èÀÇ ÇǺΰú ÀǾàǰ ½ÃÀå
Dermatological Drugs
»óǰÄÚµå : 1533966
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇǺΰú ÀǾàǰ ½ÃÀåÀº 2030³â±îÁö 614¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

2023³â¿¡ 236¾ï ´Þ·¯·Î ÃßÁ¤µÈ ÇǺΰú ÀǾàǰ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 14.6%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 614¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºñ°æ±¸ Åõ¿©´Â º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 15.3%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 437¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °æ±¸ Åõ¿© ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 12.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 64¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 19.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ ÇǺΰú ÀǾàǰ ½ÃÀåÀº 2023³â 64¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°èÀÇ 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 139¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç ¿¹Ãø ±â°£ µ¿¾ÈÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 19.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº °¢°¢ 10.9%¿Í 12.9%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÇǺΰú ÀǾàǰ ½ÃÀå : ÁÖ¿ä ÃËÁø¿äÀΰú µ¿Çâ ¿ä¾à

ÇǺΰú ÀǾàǰÀº ÇǺÎ, ¸ð¹ß, ¼ÕÅé¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áúº´°ú »óŸ¦ Ä¡·áÇϱâ À§ÇØ Æ¯º°È÷ ó¹æ µÈ ÀǾàǰÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰ¿¡´Â ¿ÜºÎ Å©¸², ¿¬°í, Á©, °æ±¸ ¾à¹°, ÁÖ»ç Ä¡·á µî ´Ù¾çÇÑ Á¦Ç°ÀÌ Æ÷ÇԵ˴ϴÙ. ¿©µå¸§, °Ç¼±, ½ÀÁø, ÁÖ»ç, ÇǺΠ°¨¿°, ÇÇºÎ¾Ï µî ´Ù¾çÇÑ ÇǺΠÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ÇǺΰú ÀǾàǰÀº Áõ»óÀ» ¿ÏÈ­ÇÏ°í ¿°ÁõÀ» ¾ïÁ¦Çϰí ÇǺÎÀÇ Ä¡À¯¿Í Àç»ýÀ» ÃËÁøÇÔÀ¸·Î½á ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù.

ÇǺΰú ÀǾàǰ ½ÃÀåÀº ÀǾàǰÀÇ ¿¬±¸ °³¹ßÀÇ Áøº¸¿Í ÇÔ²² ÇǺΠÁúȯ¿¡ ´ëÇÑ Àνİú Áø´Ü Áõ°¡·Î ÃÖ±ÙÀÇ ÇöÀúÇÑ µ¿Çâ°ú ¼ºÀåÀ» ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦¿Í ½Å±Ô ÀúºÐÀÚ ÀǾàǰÀÇ µîÀåÀº ¸¸¼ºÀûÀÌ°í ½É°¢ÇÑ ÇǺΠÁúȯÀÇ Ä¡·á »óȲ¿¡ Çõ¸íÀ» °¡Á®¿Ô½À´Ï´Ù. ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦´Â °Ç¼±°ú ¾ÆÅäÇÇ ÇǺο°°ú °°Àº ÀüÅëÀûÀÎ Ä¡·á¹ý¿¡¼­ È¿°ú°¡ Á¦ÇÑµÈ Áúº´ÀÇ Ä¡·á¿¡ ÇöÀúÇÑ È¿°ú¸¦ ³ªÅ¸³À´Ï´Ù. °Ô´Ù°¡ °øÇØ, ¶óÀÌÇÁ½ºÅ¸ÀÏ º¯È­, ³ëÈ­ µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹ÞÀº ÇǺΠÁúȯÀÇ À¯º´·üÀÇ »ó½ÂÀÌ È¿°úÀûÀÎ ÇǺΰú Ä¡·á¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ ¸¸µé¾î³»°í ÀÖ½À´Ï´Ù.

ÇǺΰú ÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú Çõ½Å, ¼ÒºñÀÚ ÇൿÀÇ ÁøÈ­, ÃÖÁ¾ ¿ëµµÀÇ È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ Áøº¸·Î º¸´Ù Àû´çÇÑ ¸ÂÃãÇü Ä¡·á°¡ °³¹ßµÇ¾î Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ°í ºÎÀÛ¿ëÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× µðÁöÅÐ °Ç°­ Ç÷§ÆûÀÇ µµÀÔÀÌ ÁøÇàµÊ¿¡ µû¶ó, ƯÈ÷ ¿ø°ÝÁö³ª ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¾Ê´Â Áö¿ª¿¡¼­ ÇǺΰú ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÇǺΠȸÃáÀ̳ª ¾ÈƼ ¿¡ÀÌ¡ Ä¡·á¸¦ ¿ä±¸ÇÏ´Â »ç¶÷ÀÌ ´Ã¾î³ª°í Àֱ⠶§¹®¿¡ ¹Ì¿ë ÇǺΰú³ª ¹Ì¿ë ÇǺΰú¸¦ Áß½ÃÇÏ°Ô µÇ´Â µî, ¼ÒºñÀÚÀÇ Çൿ µ¿Çâµµ ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë³ª ¼¼°èÀÇ ÀÇ·áºñ Áõ°¡´Â ½ÃÀåÀ» ´õ¿í ¹Ð¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî ÇǺΰú ÀǾàǰ ½ÃÀåÀº ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô ÁøÈ­Çϰí ÀÖÀ¸¸ç, ÇâÈÄ ¼ö³â°£ Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(Àü 86°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Dermatological Drugs Market to Reach US$61.4 Billion by 2030

The global market for Dermatological Drugs estimated at US$23.6 Billion in the year 2023, is expected to reach US$61.4 Billion by 2030, growing at a CAGR of 14.6% over the analysis period 2023-2030. Parenteral Administration, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$43.7 Billion by the end of the analysis period. Growth in the Oral Administration segment is estimated at 12.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.4 Billion While China is Forecast to Grow at 19.6% CAGR

The Dermatological Drugs market in the U.S. is estimated at US$6.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.9 Billion by the year 2030 trailing a CAGR of 19.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 12.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Global Dermatological Drugs Market - Key Drivers and Trends Summarized

Dermatological drugs are medications specifically formulated to treat diseases and conditions affecting the skin, hair, and nails. These drugs encompass a wide range of products, including topical creams, ointments, gels, oral medications, and injectable treatments. They are used to manage a variety of dermatological conditions such as acne, psoriasis, eczema, rosacea, skin infections, and skin cancer. Dermatological drugs play a crucial role in improving patients' quality of life by alleviating symptoms, reducing inflammation, and promoting skin healing and regeneration.

The dermatological drugs market has witnessed significant advancements and growth over recent years, driven by increasing awareness and diagnosis of skin conditions, coupled with advancements in pharmaceutical research and development. The advent of biologics and novel small-molecule drugs has revolutionized the treatment landscape for chronic and severe dermatological diseases. Biologics, in particular, have shown remarkable efficacy in treating conditions like psoriasis and atopic dermatitis, where traditional treatments have limited effectiveness. Additionally, the rising prevalence of skin diseases, influenced by factors such as pollution, changing lifestyles, and aging populations, has created a sustained demand for effective dermatological treatments.

The growth in the dermatological drugs market is driven by several factors, including technological innovations, evolving consumer behaviors, and expanding end-use applications. Technological advancements have led to the development of more targeted and personalized therapies, improving treatment outcomes and reducing side effects. Furthermore, the increasing adoption of telemedicine and digital health platforms has enhanced access to dermatological care, particularly in remote and underserved areas. Consumer behavior trends, such as the growing emphasis on aesthetic and cosmetic dermatology, have also fueled market growth, as individuals seek treatments for skin rejuvenation and anti-aging. Additionally, the expansion of healthcare infrastructure in emerging markets and the rising healthcare expenditure globally are expected to further propel the market. These factors collectively contribute to a dynamic and rapidly evolving dermatological drugs market, poised for continued growth in the coming years.

Select Competitors (Total 86 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â